Sarada Gurubhagavatula
Advanced in Lung Cancer

Dr. Sarada Gurubhagavatula

Hematology | Oncology
Atlantic Health
Summit Medical Group Oncology
95 Madison Avenue, Floor 2, 
Morristown, NJ 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Advanced in Lung Cancer
Atlantic Health
Summit Medical Group Oncology
95 Madison Avenue, Floor 2, 
Morristown, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sarada Gurubhagavatula is a Hematologist and an Oncologist in Morristown, New Jersey. Dr. Gurubhagavatula is rated as an Advanced provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, and Squamous Cell Lung Carcinoma. Dr. Gurubhagavatula is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 6 clinical trials in the study of Lung Cancer.

Graduate Institution
Johns Hopkins University Medical School
Residency
Brigham and Women's Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NJ
Board Certifications
American Board Of Internal Medicine
Fellowships
Dana-Farber Cancer Institute
Hospital Affiliations
Morristown Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Guardian Life Insurance Company
  • MEDICARE PDP
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Summit Medical Group Oncology
95 Madison Avenue, Floor 2, Morristown, NJ 07960
Call: 973-538-5210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Enrollment Status: Recruiting
Publish Date: April 01, 2025
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Osimertinib, Ramucirumab
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: December 20, 2024
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Chemotherapy
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
Journal: Cancer
Published: June 09, 2025
Similar Doctors
Elite in Lung Cancer
Dr. Mark G. Kris
Oncology
Elite in Lung Cancer
Dr. Mark G. Kris
Oncology

Memorial Solid Tumor Group

353 E 68th St, 
New York, NY 
 (11.5 miles away)
646-422-4300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Kris is an Oncologist in New York, New York. Dr. Kris is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

Gregory J. Riely
Elite in Lung Cancer
Dr. Gregory J. Riely
Oncology
Elite in Lung Cancer
Dr. Gregory J. Riely
Oncology

Memorial Solid Tumor Group

530 E 74th St, 
New York, NY 
 (11.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Riely is an Oncologist in New York, New York. Dr. Riely is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Thymic Epithelial Tumor, Tissue Biopsy, and Liver Embolization. Dr. Riely is currently accepting new patients.

Jamie E. Chaft
Elite in Lung Cancer
Dr. Jamie E. Chaft
Oncology
Elite in Lung Cancer
Dr. Jamie E. Chaft
Oncology

Memorial Solid Tumor Group

530 E 74th St, 
New York, NY 
 (11.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jamie Chaft is an Oncologist in New York, New York. Dr. Chaft is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Chaft is currently accepting new patients.

VIEW MORE LUNG CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gurubhagavatula's expertise for a condition
ConditionClose
    • Distinguished
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Gurubhagavatula is
      Distinguished
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Lung Adenocarcinoma
      Dr. Gurubhagavatula is
      Distinguished
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Pleuropulmonary Blastoma
      Dr. Gurubhagavatula is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Small Cell Lung Cancer (SCLC)
      Dr. Gurubhagavatula is
      Distinguished
      . Learn about Small Cell Lung Cancer (SCLC).
      See more Small Cell Lung Cancer (SCLC) experts
    • Squamous Cell Lung Carcinoma
      Dr. Gurubhagavatula is
      Distinguished
      . Learn about Squamous Cell Lung Carcinoma.
      See more Squamous Cell Lung Carcinoma experts
    • Advanced
    • Breast Cancer
      Dr. Gurubhagavatula is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Gurubhagavatula is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Familial Pancreatic Cancer
      Dr. Gurubhagavatula is
      Advanced
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Inflammatory Breast Cancer
      Dr. Gurubhagavatula is
      Advanced
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Large-Cell Lung Carcinoma
      Dr. Gurubhagavatula is
      Advanced
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    • Lung Cancer
      Dr. Gurubhagavatula is
      Advanced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    View All 10 Advanced Conditions
    • Experienced
    • Adenoid Cystic Carcinoma
      Dr. Gurubhagavatula is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Gurubhagavatula is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Gurubhagavatula is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anemia
      Dr. Gurubhagavatula is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    • Angiosarcoma
      Dr. Gurubhagavatula is
      Experienced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Childhood Iron Deficiency Anemia
      Dr. Gurubhagavatula is
      Experienced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.